The expanded FDA 510(k) indications for COHERE allow it to be used at multiple levels in the cervical spine (C2 – T1) with both autograft and allograft. In addition, COHERE received a new ICD code from the Center of Medicare & Medicaid Services (CMS) in October 2017. COHERE is the only product approved for use with the new code, signifying CMS' recognition of the innovation and potential clinical and tracking benefits of using Porous PEEK technology.
Previously available from Vertera Spine.